Synthetic method and application of aza-quinolone compound

By developing new azaquinolones, the problems of high toxic side effects and poor permeability of the blood-brain barrier in the treatment of cancer are solved, and efficient inhibition of PARP-1 and effective crossing of the blood-brain barrier are achieved. , provides a new treatment plan for patients with brain metastasis of HRD+ breast cancer.

CN119019391AInactive Publication Date: 2024-11-26SHANDONG SHINING PHARM CO LTD

Patent Information

Application Number
CN202411136931.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing PARP-1 inhibitors have high toxic side effects and poor permeability of the blood-brain barrier when treating cancer, making it difficult to effectively cross the blood-brain barrier, and have limited efficacy in patients with brain metastasis of HRD+ breast cancer.

Method used

A new class of azaquinolones has been developed, with better pharmacodynamic properties and longer half-life, and its inhibitory activity against PARP-1 and blood-brain barrier permeability are improved by optimizing the compound structure.

Benefits of technology

The novel compound shows high PARP-1 inhibitory activity and excellent pharmacodynamic performance, which can effectively cross the blood-brain barrier, provide new treatment plans, reduce toxic side effects, and improve the efficacy of cancer, especially in HRD+ breast cancer Treatment effects in patients with brain metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019391A_ABST
    Figure CN119019391A_ABST
Patent Text Reader

Abstract

The invention discloses a compound represented by the following formula (I) and pharmaceutically acceptable salt and medical application thereof. The compound can be used for primary and secondary brain malignant tumors, and has good poly (adenosine diphosphate-ribose polymerase) (PARP) inhibitory activity and excellent pharmacodynamic performance. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to a synthesis method and application of a class of azaquinolone compounds. Background Art

[0002] Poly (ADP-ribose) polymerase (PARP) is a type of ribozyme in eukaryotic cells, involved in a variety of cellular processes, such as DNA damage repair, genome stability and programmed cell death. It was first reported in 1963. The PARP family contains at least 18 subtypes with different structures and cellular functions, including PARP-1, PARP-2, PARP-4, Tankyrase-1 and 2, and other PARP-3. 16. PARP is composed of four domains, including DNA binding domain, caspase cleavage domain, self-modification domain and catalytic domain. Among them, PARP-1 was discovered first. Although PARP-1 and PARP-2 have similar structures, most of the DNA damage repair process is completed by PARP-1, so the research on PARP inhibitor drugs mainly focuses on PARP-1 inhibitors.

[0003] Many types of cancer cells are more dependent on PARP than regular cells, making PARP inhibitor drugs the most attractive targets in cancer treatment. PARP-1 inhibitors can be used as sensitizers to improve the efficacy of anticancer drugs. Chemotherapy or radiotherapy drugs inhibit or kill cells by destroying the structure of tumor cell DNA, and tumor cells can repair damaged DNA cells through PARP-1, thereby developing resistance to chemotherapy drugs. Therefore, PARP-1 inhibitor drugs can be combined with chemotherapy drugs to cope with drug resistance, thereby reducing the dosage and improving the efficacy. In addition, studies have shown that the use of PARP-1 inhibitors alone can kill DNA repair-deficient cancer cells, especially BRCA-1 / 2 missing or mutated cancer cells. Based on years of research on PARP inhibitors, PARP-1 inhibitors have become one of the hot spots in cancer drug development, and the reliability and feasibility of this target have been confirmed.

[0004] Based on years of research on PARP inhibitors, PARP-1 inhibitors have become one of the hot spots in cancer drug development, and the reliability and feasibility of this target have been confirmed. AstraZeneca's Olaparib, trade name Lynparza, was approved by EMA and FDA in 2014 for single-drug treatment of advanced ovarian cancer related to BRCA gene mutations after chemotherapy. In addition, other drugs under development, such as AstraZeneca's AZD5305 and AZD9574, are in the clinical trial stage.

[0005]

[0006] There is an unmet medical need for effective and safe PARP inhibitors, particularly PARP inhibitors that are selective for PARP-1.

[0007] The present invention discovered a new type of azaquinolone compound in the process of studying PARP-1 inhibitors. This type of compound has the characteristics of lower toxicity and side effects, effectively increased blood-brain barrier passage rate, longer half-life, and better safety. It is expected that this type of inhibitor will have good therapeutic effects, is expected to overcome drug resistance and toxicity problems, and provide a new treatment plan for patients with HRD+ breast cancer brain metastasis, and has good development prospects. Summary of the invention

[0008] Problems to be solved by the present invention

[0009] The invention provides a novel azaquinolone compound as a poly(ADP-ribose) polymerase inhibitor. The structural compound has the advantages of better pharmacodynamic performance and higher metabolic stability.

[0010] Furthermore, the present invention provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and use.

[0011] Solutions for solving problems

[0012] The present invention provides a compound represented by the following formula (I) and a pharmaceutically acceptable salt thereof:

[0013]

[0014] Wherein, R1 is selected from hydrogen, C1-C6 alkyl or C3-C8 cycloalkyl;

[0015] R2 and R3 are each independently selected from H, halo, C1-C3 alkyl, deuterated C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy;

[0016] R4 is selected from C1-C3 alkyl, deuterated C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy;

[0017] A and B are each independently selected from N and C(H), provided that A and B are not N or C(H) at the same time;

[0018] X is selected from N and C(H);

[0019] It can be single key or double key.

[0020] Further,

[0021] R1 is selected from C1-C4 alkyl or C3-C6 cycloalkyl, preferably methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl; more preferably hydrogen, methyl, ethyl, cyclopropyl;

[0022] R2 and R3 are each independently selected from H and halo, the halo is preferably selected from fluorine, chlorine, bromine; more preferably fluorine;

[0023] R4 is selected from methyl or methyl substituted with 1 to 3 deuterium atoms; more preferably methyl or deuterated methyl;

[0024] Preferably, A and B are each independently selected from N and C(H);

[0025] Preferably, X is selected from N and C(H);

[0026] It can be single key or double key.

[0027] Furthermore, the compound of general formula (I) or a pharmaceutically acceptable salt thereof is one of the following compounds:

[0028]

[0029] The compound of the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is an inorganic salt or an organic salt, the inorganic salt includes hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; the organic salt is selected from acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, fumarate, maleate, lactate, malate, citrate, tartrate, methanesulfonate, isosulfonate, benzenesulfonate, and salicylate.

[0030] Another object of the present invention is to provide a pharmaceutical composition, which contains the compound of the general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.

[0031] In another aspect, the present invention provides use of the compound of the above general formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof in the preparation of a drug for use as a PARP1 inhibitor.

[0032] In another aspect, the present invention provides use of the compound of the above general formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof in the preparation of a drug for treating cancer.

[0033] The cancer mentioned in the present invention can be selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, blood cancer, gastrointestinal cancer (such as gastric cancer and colorectal cancer), or lung cancer.

[0034] The beneficial effect of the present invention is to design a new type of azaquinolone compound, which has the biological function of inhibiting PARP1, thereby providing a new means for finding new treatments for cancer, metabolic and immune diseases, cardiovascular diseases, and neurological diseases.

[0035] Beneficial Effects

[0036] The azaquinolone compound with a structure shown in general formula (I) provided by the present invention can be used for primary and secondary brain malignant tumors, and has good poly (ADP-ribose) polymerase (PARP) inhibitory activity and excellent pharmacodynamic properties. DETAILED DESCRIPTION

[0037] Hereinafter, the present invention will be described in detail. Before describing, it should be understood that the terms used in this specification and the appended claims should not be interpreted as being limited to the general meaning and dictionary meaning, but should be interpreted according to the meaning and concept corresponding to the technical aspects of the present invention on the basis of the principle that the inventor is allowed to appropriately define the terms for the best interpretation. Therefore, the descriptions presented here are only preferred examples for illustrative purposes and are not intended to limit the scope of the present invention, so that it should be understood that other equivalents or improvements can be obtained therefrom without departing from the spirit and scope of the present invention.

[0038] The following examples are only listed as examples of embodiments of the present invention and do not constitute any limitation to the present invention. It can be understood by those skilled in the art that modifications within the scope of the essence and concept of the present invention fall within the scope of protection of the present invention. Unless otherwise specified, the reagents and instruments used in the following examples are all commercially available products.

[0039] Hereinafter, the preferred embodiments of the present disclosure will be described in detail with reference. Before the description, it should be understood that the terms used in the specification and the appended claims should not be interpreted as limited to the general and dictionary meanings, but should be interpreted based on the principle of allowing the inventor to appropriately define the terms for the best interpretation, based on the meaning and concept corresponding to the technical level of the present invention. Therefore, the description herein is only a preferred example for illustrative purposes, and is not intended to limit the scope of the present invention, so it should be understood that other equivalent implementations and modifications can be made without departing from the spirit and scope of the present invention.

[0040] As used herein, the terms "include", "comprising", "having", "containing" or any other similar terms are open-ended transitional phrases, which are intended to cover non-exclusive inclusions. For example, a composition or article containing multiple elements is not limited to the elements listed herein, but may also include other elements that are not explicitly listed but are generally inherent to the composition or article. In addition, unless otherwise expressly stated, the term "or" refers to an inclusive "or" rather than an exclusive "or". For example, any of the following situations satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist). In addition, as used herein, the terms "include", "comprising", "having", and "containing" should be interpreted as having been specifically disclosed and simultaneously covering closed or semi-closed transitional phrases such as "consisting of" and "consisting essentially of".

[0041] In this article, all features or conditions defined in the form of numerical ranges or percentage ranges are only for brevity and convenience. Accordingly, the description of numerical ranges or percentage ranges should be deemed to have covered and specifically disclosed all possible secondary ranges and individual values ​​within the range, especially integer values. For example, the range description of "1 to 8" should be deemed to have specifically disclosed all secondary ranges such as 1 to 7, 2 to 8, 2 to 6, 3 to 6, 4 to 8, 3 to 8, etc., especially secondary ranges defined by all integer values, and should be deemed to have specifically disclosed individual values ​​such as 1, 2, 3, 4, 5, 6, 7, 8, etc. within the range. Unless otherwise specified, the above interpretation method applies to all contents of the entire present invention, regardless of whether the range is broad or not.

[0042] If the quantity or other numerical value or parameter is expressed as a range, a preferred range or a series of upper and lower limits, it should be understood that all ranges consisting of any upper limit or preferred value of the range and the lower limit or preferred value of the range have been specifically disclosed herein, regardless of whether these ranges are disclosed separately. In addition, if a numerical range is mentioned herein, unless otherwise specified, the range should include its endpoints and all integers and fractions within the range.

[0043] In this document, under the premise of achieving the purpose of the invention, numerical values ​​should be understood to have the accuracy of the number of significant digits of the numerical value. For example, the number 40.0 should be understood to cover the range from 39.50 to 40.49.

[0044] In the present invention, "C1-C4 alkyl" refers to a saturated linear or branched monovalent hydrocarbon group of 1 to 4 carbon atoms. Examples include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl and 2-methyl-2-propyl.

[0045] In the present invention, "C3-C6 cycloalkyl group" refers to a cycloalkyl group having 3 to 6 carbon atoms.

[0046] In the present invention, "administering" or "giving" a subject compound means providing the subject in need of treatment with the compound of the present invention. <Compound or pharmaceutically acceptable salt thereof>

[0047] The present invention provides a novel azaquinolone compound or a pharmaceutically acceptable salt thereof as a poly(ADP-ribose) polymerase (PARP) inhibitor, the structural formula of which is shown in general formula (I):

[0048]

[0049] <Pharmaceutical Composition>

[0050] The present invention also provides a pharmaceutical composition comprising the compound of the general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent.

[0051] The compounds of the present invention or their pharmaceutically acceptable salts can be formulated into solid preparations for oral administration, including, but not limited to capsules, tablets, pills, powders, granules, etc. In these solid dosage forms, the compounds of the general formula (I) of the present invention are mixed as active ingredients with at least one conventional inert excipient (or carrier), for example, with sodium citrate or dicalcium phosphate. Or mixed with the following ingredients: (1) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (2) binders, such as hydroxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose, gum arabic, etc.; (3) humectants, such as glycerol, etc.; (4) disintegrators, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates and sodium carbonate, etc.; (5) solubilizers, such as paraffin, etc.; (6) absorption accelerators, such as quaternary ammonium compounds, etc.; (7) wetting agents, such as cetyl alcohol and glyceryl monostearate, etc.; (8) adsorbents, such as kaolin, etc.; (9) lubricants, such as talc, calcium stearate, solid polyethylene glycol, sodium lauryl sulfate, etc., or mixtures thereof. Capsules, tablets and pills may also contain buffers.

[0052] The solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be coated or microencapsulated with coating and shell materials such as enteric coatings and other materials known in the art. They can contain opacifiers, and the release of the active ingredient in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active ingredient can also be formed into microcapsules with one or more of the above-mentioned excipients.

[0053] The compounds of the present invention or their pharmaceutically acceptable salts can be formulated into liquid dosage forms for oral administration, including, but not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, tinctures, etc. In addition to the compound of formula (I) or its pharmaceutically acceptable salt as an active ingredient, the liquid dosage form may contain inert diluents conventionally used in the art, such as water and other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil, sesame oil, etc. or mixtures of these substances, etc. In addition to these inert diluents, the liquid dosage form of the present invention may also include conventional adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and spices, etc.

[0054] The suspending agent includes, for example, ethoxylated stearyl alcohol, polyoxyethylene sorbitol, and sorbitan, microcrystalline cellulose, agar, etc. or a mixture of these substances.

[0055] The compounds of the present invention and their pharmaceutically acceptable salts can be formulated into dosage forms for parenteral injection, including, but not limited to, physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions and dispersions. Suitable carriers, diluents, solvents, excipients include water, ethanol, polyols and suitable mixtures thereof.

[0056] The compound of the present invention or its pharmaceutically acceptable salt can be configured into dosage forms for topical administration, including ointments, powders, suppositories, drops, sprays and inhalants, etc. The compound of the present invention of general formula (I) or its pharmaceutically acceptable salt as an active ingredient is mixed with a physiologically acceptable carrier and optional preservatives, buffers, and propellants that may be required under sterile conditions.

[0057] The pharmaceutical composition of the present invention comprises a compound of the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier, excipient, and diluent. When preparing the pharmaceutical composition, the compound of the general formula (I) of the present invention or a pharmaceutically acceptable salt thereof is usually mixed with a pharmaceutically acceptable carrier, excipient, or diluent. The content of the compound of the general formula (I) or a pharmaceutically acceptable salt thereof can be 0.01-1000 mg, for example 0.05-800 mg, 0.1-500 mg, 0.01-300 mg, 0.01-200 mg, 0.05-150 mg, 0.05-50 mg, etc.

[0058] <Purpose>

[0059] The present invention also provides use of the compound of general formula (I) or a pharmaceutically acceptable salt thereof in preparing a compound for treating cancer in a mammal.

[0060] The compound of general formula (I) or a pharmaceutically acceptable salt thereof is used for treating diseases such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer in mammals including humans by inhibiting the activity of poly(ADP-ribose) polymerase (PARP), and the method comprises administering a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof to the mammal including humans.

[0061] A "therapeutically effective amount" is an amount of a compound of the invention that is effective to produce a biological or medical response in a subject (eg, to reduce or inhibit enzyme or protein activity, or to improve symptoms, alleviate conditions, slow or delay disease progression, or prevent disease).

[0062] The cancers mentioned in the present invention include lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin melanoma or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, gallbladder cancer, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue carcinoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer or ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system (CNS) cancer, primary central nervous system lymphoma, spinal cord axis cancer, brain stem glioma, pituitary adenoma, etc.

[0063] The compounds of the present invention or their pharmaceutically acceptable salts can be administered to mammals, including humans, orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), topically (powders, ointments, drops) or intratumorally.

[0064] The compound or pharmaceutically acceptable salt thereof of the present invention can be administered alone, or in combination with other pharmaceutically acceptable therapeutic agents, or in combination with other anti-tumor drugs. This combined therapy can be achieved by using the various components of the treatment simultaneously, sequentially or separately. The therapeutic agent includes, but is not limited to, anti-tumor drugs acting on the chemical structure of DNA, such as cisplatin, anti-tumor drugs affecting nucleotide synthesis, such as methotrexate, 5-fluorouracil, etc., anti-tumor drugs affecting nucleic acid transcription, such as doxorubicin, epirubicin, aclarubicin, etc., anti-tumor drugs acting on microtubule synthesis, such as paclitaxel, vinorelbine, etc., aromatase inhibitors such as aminoglutethimide, letrozole, arinide, etc., cell signaling pathway inhibitors such as ALK inhibitors crizotinib, ceritinib, alectinib, lorlatinib, etc. Anti-tumor monoclonal antibodies, immunosuppressants PD-1, PD-L1, etc., the components to be combined can be administered simultaneously or sequentially, in the form of a single preparation or in the form of different preparations. The combination includes not only a combination of one or other active agents of the compound of the present invention, but also a combination of two or more other active agents of the compound of the present invention.

[0065] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually based on conventional conditions.

[0066] 7-(Bromomethyl)-3-cyclopropyl-1,5-naphthyridin-2(1H)-one (Intermediate 7)

[0067]

[0068] Preparation of 6-formyl-5-nitronicotinic acid ethyl ester (intermediate 2)

[0069] Dissolve 6-methyl-5-nitronicotinic acid ethyl ester (intermediate 1) (10g, 47.62mmol) in 1,4-dioxane (100mL), add selenium dioxide (7.93g, 71.43mmol), and heat the mixture to 110°C for 20 hours. After the reaction, the reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column. 6-formyl-5-nitronicotinic acid ethyl ester (intermediate 2) (8.5g, 80%) was obtained as a brown oil. ESI-MS m / z: 225[M+H] +

[0070] Preparation of ethyl (E)-6-(2-cyclopropyl-3-methoxy-3-oxopropyl-1-en-1-yl)-5-nitronicotinate (Intermediate 3) Sodium hydride (3.79 g, 94.85 mmol) was dispersed in anhydrous THF (100 mL) at 0°C, and cyclopropaneacetic acid, α-(diethoxyphosphino)-, ethyl ester (25.04 g, 94.85 mmol) was slowly added dropwise. The resulting mixture was stirred at 0°C for 10 minutes, slowly heated to 40°C and stirred for 5 minutes. The reaction mixture was cooled to -78°C, and then 6-formyl-5-nitronicotinate (Intermediate 2) (8.5 g, 37.94 mmol) in THF (50 mL) was slowly added dropwise. After the reaction was completed, the mixture was quenched with saturated NH4Cl solution and extracted with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column. Ethyl (E)-6-(2-cyclopropyl-3-methoxy-3-oxopropyl-1-en-1-yl)-5-nitronicotinate (Intermediate 3) (8 g, 63%) was obtained as a yellow oil. ESI-MS m / z: 335 [M+H] +

[0071] Preparation of ethyl 7-cyclopropyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxylate (Intermediate 4)

[0072] Dissolve ethyl (E)-6-(2-cyclopropyl-3-methoxy-3-oxopropyl-1-en-1-yl)-5-nitronicotinate (Intermediate 3) (8 g, 23.95 mmol) in ethanol (100 mL), add Pd / C (0.8 g) (10%), and stir at room temperature overnight under a hydrogen atmosphere. After the reaction is completed, filter through celite and concentrate the filtrate under reduced pressure. Add 100 mL of 4M HCl in dioxane. Stir at room temperature for 2 hours. After the reaction is completed, concentrate under reduced pressure to obtain 7-cyclopropyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxylic acid ethyl ester (Intermediate 4) (5 g, 80%) as a white solid. ESI-MS m / z: 261 [M+H] +

[0073] Preparation of ethyl 7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate (Intermediate 5)

[0074] Dissolve 7-cyclopropyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxylic acid ethyl ester (Intermediate 4) (5g, 19.23mmol) in 1,4-dioxane (50mL), add DDQ (5.24g, 23.07mmol), heat under reflux for 5 hours, and concentrate under reduced pressure after the reaction is completed. Add saturated NaHCO3 and stir at room temperature for 1 hour. Filter. Wash the solid with ether. Obtain 7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylic acid ethyl ester (Intermediate 5) (4.2g, 84%) as a light brown solid. ESI-MSm / z: 259[M+H] +

[0075] Preparation of 3-cyclopropyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (Intermediate 6)

[0076] Dissolve 7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylic acid ethyl ester (Intermediate 5) (4.2 g, 16.28 mmol) in anhydrous THF (100 mL), add lithium aluminum tetrahydride (1.24 g, 32.56 mmol) in batches at 0°C, react at 0°C for 2 hours, add water to quench after the reaction, filter, and concentrate the filtrate under reduced pressure. Obtain 3-cyclopropyl-7-(hydroxymethyl)-1,5-naphthyridine-2(1H)-one (Intermediate 6) (2.0 g, 57%) as a light yellow solid. ESI-MS m / z: 217 [M+H] +

[0077] Preparation of 7-(bromomethyl)-3-cyclopropyl-1,5-naphthyridin-2(1H)-one (Intermediate 7)

[0078] 3-Cyclopropyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (Intermediate 6) (2.0 g, 9.26 mmol) and triphenylphosphine (3.64 g, 13.89 mmol) were dissolved in dichloromethane (30 mL), and carbon tetrabromide (4.33 g, 13.89 mmol) was added in batches at 0°C. Stir at 0°C for 2 hours. After the reaction was completed, it was concentrated under reduced pressure. The crude product was purified by silica gel column. 7-(bromomethyl)-3-cyclopropyl-1,5-naphthyridin-2(1H)-one (Intermediate 7) (1.3 g, 50%) was obtained as a light yellow solid. ESI-MS m / z: 279 [M+H] +

[0079] Preparation of 7-(bromomethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Intermediate 8)

[0080]

[0081] The synthesis method refers to the preparation of intermediate 7, wherein ethyl 2-(diethoxyphosphino)butyrate replaces α-(diethoxyphosphino)-, ethyl ester. Pale yellow solid. ESI-MS m / z: 267, 269 [M+H] + .

[0082] 7-(Bromomethyl)-8-fluoro-3-methylquinolin-2(1H)-one (Intermediate 14)

[0083]

[0084] Preparation of methyl (4-bromo-3-fluoro-2-nitrophenyl) alanine ester (Intermediate 10)

[0085] 1-Bromo-2,4-difluoro-3-nitrobenzene (Intermediate 9) (10.0 g, 42.19 mmol) was dissolved in DMF (100 mL), and alanine methyl ester hydrochloride (5.72 g, 42.19 mmol) and DIPEA (22 mL, 126.57 mmol) were added. The reaction solution was stirred at room temperature for 18 hours. After the reaction was completed, it was diluted with ethyl acetate and washed with water 5 times to remove DMF. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product. Methyl (4-bromo-3-fluoro-2-nitrophenyl) alanine ester (Intermediate 10) (7.4 g, 55%) was obtained by beating with DCM as a light yellow solid. ESI-MS m / z: 321 [M+H] +

[0086] Preparation of 7-bromo-8-fluoro-3-methyl-3,4-dihydroquinolin-2(1H)-one (Intermediate 11)

[0087] Methyl (4-bromo-3-fluoro-2-nitrophenyl) alanine ester (intermediate 10) (7.4 g, 23.05 mmol) and ammonium chloride (6.16 g, 115.25 mmol) were dissolved in methanol (100 mL) and water (10 mL). Zinc powder (7.54 g, 115.25 mmol) was added in batches at 0°C and stirred at room temperature for 2 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the intermediate was added with 100 mL of 4M HCl in dioxane solution. After stirring at room temperature for 3 hours, the reaction was concentrated under reduced pressure, and the crude product was purified by silica gel column. 7-Bromo-8-fluoro-3-methyl-3,4-dihydroquinolin-2(1H)-one (intermediate 11) (3.0 g, 50%) was obtained as a light yellow liquid. ESI-MS m / z: 259 [M+H] +

[0088] Preparation of 7-bromo-8-fluoro-3-methylquinolin-2(1H)-one (Intermediate 12)

[0089] Dissolve 7-bromo-8-fluoro-3-methyl-3,4-dihydroquinolin-2(1H)-one (Intermediate 11) (3.0 g, 11.58 mmol) in dichloromethane (50 mL), add DDQ (3.15 g, 13.89 mmol), stir at room temperature for 5 hours, and concentrate under reduced pressure after the reaction is completed. Add saturated NaHCO3, stir at room temperature for 1 hour, and filter. Wash the solid with ether. Obtain 7-bromo-8-fluoro-3-methylquinolin-2(1H)-one (Intermediate 12) (2.2 g, 73%) as an off-white solid. ESI-MS m / z: 258 [M+H] + Preparation of 8-fluoro-7-(hydroxymethyl)-3-methylquinolin-2(1H)-one (Intermediate 13)

[0090] Dissolve (tributyltin)methanol (3.3g, 10.27mmol) and 7-bromo-8-fluoro-3-methylquinolin-2(1H)-one (intermediate 12) (2.2g, 8.56mmol) in 1,4-dioxane (50mL), add Xphos Pd G2 (336mg, 0.428mmol), heat to 80℃ under nitrogen atmosphere for 5 hours, concentrate under reduced pressure after the reaction, and purify the crude product by silica gel column. 8-Fluoro-7-(hydroxymethyl)-3-methylquinolin-2(1H)-one (intermediate 13) (1.2g, 67%) was obtained as a white solid. ESI-MS m / z: 209[M+H] +

[0091] Preparation of 7-(bromomethyl)-8-fluoro-3-methylquinolin-2(1H)-one (Intermediate 14)

[0092] 8-Fluoro-7-(hydroxymethyl)-3-methylquinolin-2(1H)-one (Intermediate 13) (1.2 g, 5.77 mmol) and triphenylphosphine (2.26 g, 8.65 mmol) were dissolved in dichloromethane (30 mL), and carbon tetrabromide (2.87 g, 8.65 mmol) was added in batches at 0°C. Stir at 0°C for 2 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column. 7-(bromomethyl)-8-fluoro-3-methylquinolin-2(1H)-one (Intermediate 14) (0.8 g, 51%) was obtained as a light gray solid. ESI-MS m / z: 272[M+H] +

[0093] 7-(Bromomethyl)quinolin-2(1H)-one (Intermediate 17)

[0094]

[0095] The synthesis method refers to the preparation of intermediate 14. Light gray solid. ESI-MS m / z: 238 [M+H]+

[0096] 7-(Bromomethyl)-8-fluoroquinolin-2(1H)-one (Intermediate 21)

[0097]

[0098] Preparation of 7-bromo-8-fluoroquinolin-2(1H)-one (Intermediate 19)

[0099] 4-Bromo-3-fluorobenzene-1,2-diamine (Intermediate 18) (5.0 g, 24.39 mmol) was dissolved in toluene (50 mL), methyl glyoxylate (3.2 g, 36.58 mmol) was added, and the reaction solution was heated to reflux for 1 hour. After the reaction was completed, it was concentrated under reduced pressure and the crude product was purified by silica gel column. 7-Bromo-8-fluoroquinolin-2(1H)-one (Intermediate 19) (4.0 g, 67%) was obtained as an off-white solid. ESI-MS m / z: 243 [M+H] +

[0100] 8-Fluoro-7-(hydroxymethyl)quinolin-2(1H)-one (Intermediate 20), light brown solid. ESI-MS m / z: 195 [M+H] + and 7-(bromomethyl)-8-fluoroquinolin-2(1H)-one (Intermediate 21), light grey solid, ESI-MS m / z: 257

[0101] [M+H] + The synthesis of the intermediate 14 was referred to.

[0102] 6-Fluoro-N-methyl-5-(piperazin-1-yl)picolinamide (Intermediate 26)

[0103]

[0104] Preparation of methyl 5-bromo-6-fluoropicolinate (Intermediate 23)

[0105] Methyl 5-bromopicolinate (Intermediate 19) (5 g, 23.14 mmol) was dissolved in acetonitrile (50 mL), and silver (II) fluoride (10.1 g, 69.42 mmol) was added and stirred at room temperature overnight. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column. Methyl 5-bromo-6-fluoropicolinate (Intermediate 23) (4.0 g, 74%) was obtained as an off-white solid. ESI-MS m / z: 234 [M+H] +

[0106] Preparation of tert-butyl 4-(2-fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylate (Intermediate 24)

[0107] 5-Bromo-6-fluoropicolinic acid methyl ester (Intermediate 23) (4g, 17.09mmol) and tert-butyl piperazine-1-carboxylate (4.77g, 25.63mmol) were dissolved in 1,4-dioxane (100mL), and RuphosPd-G3 (715mg, 0.85mmol) and cesium carbonate (11.1g, 34.18mmol) were added. The mixture was heated to 80°C and stirred for 16 hours under a nitrogen atmosphere. After the reaction was completed, water was added and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by a silica gel column. 4-(2-fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 24) (3.5g, 60%) was obtained as a light yellow solid. ESI-MS m / z: 340[M+H] +

[0108] Preparation of tert-butyl 4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazine-1-carboxylate (Intermediate 25)

[0109] 4-(2-Fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 24) (2g, 5.90mmol) was dissolved in methylamine (20mL, 5.90mmol, 33wt% ethanol solution), stirred at room temperature for 16 hours, and the reaction was completed. Concentrated under reduced pressure, and the resulting crude product was purified by silica gel column. 4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 25) (1.4g, 70%) was obtained as a light yellow solid. ESI-MS m / z: 339[M+H] +

[0110] Preparation of 6-fluoro-N-methyl-5-(piperazin-1-yl)picolinamide (Intermediate 26)

[0111] 4-(2-Fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 25) (1.4 g, 4.14 mmol) was dissolved in dioxane (20 mL), and a 4M HCl solution in dioxane (5 mL) was added and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was neutralized with a saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 6-fluoro-N-methyl-5-(piperazin-1-yl)pyridineamide (Intermediate 26) (0.7 g, 71%) as a light yellow solid. ESI-MS m / z: 239 [M+H] +

[0112] 6-Fluoro-N-(methyl-d3)-5-(piperazin-1-yl)picolinamide (Intermediate 29)

[0113]

[0114] Preparation of 5-(4-(tert-Butyloxycarbonyl)piperazin-1-yl)-6-fluoropicolinic acid (Intermediate 27)

[0115] 4-(2-Fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 24) (1 g, 2.95 mmol) was dissolved in tetrahydrofuran (15 mL), and a solution of lithium hydroxide (212 mg, 8.85 mmol) in water (5 mL) was added. The reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, the organic solvent was removed by concentration under reduced pressure, and the pH was adjusted to 5-6 with 1N dilute hydrochloric acid. Solids precipitated, filtered, and dried to obtain 5-(4-(tert-butyloxycarbonyl)piperazine-1-yl)-6-fluoropicolinic acid (Intermediate 27) (0.8 g, 83%) as a light yellow solid. ESI-MS m / z: 324 [MH] - Preparation of tert-butyl 4-(2-fluoro-6-(methyl-d3)carbamoyl)pyridin-3-yl)piperazine-1-carboxylate (Intermediate 28)

[0116] 5-(4-(tert-Butyloxycarbonyl)piperazine-1-yl)-6-fluoropicolinic acid (Intermediate 27) (0.5 g, 1.54 mmol) and deuterated methylamine hydrochloride (0.13 g, 1.85 mmol) were dissolved in DMF (2 mL), and DIPEA (0.8 mL, 4.62 mmol) and HATU (0.70 g, 1.85 mmol) were added. The mixture was stirred at room temperature for 16 hours. After the reaction was completed, it was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column. 4-(2-fluoro-6-(methyl-d3)carbamoyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 28) (0.35 g, 67%) was obtained as a light yellow solid. ESI-MS m / z: 342 [M+H] +

[0117] Preparation of 6-fluoro-N-(methyl-d3)-5-(piperazin-1-yl)picolinamide (Intermediate 29)

[0118] Dissolve tert-butyl 4-(2-fluoro-6-(methyl-d3)carbamoyl)pyridin-3-yl)piperazine-1-carboxylate (Intermediate 28) (0.35 g, 1.03 mmol) in dioxane (10 mL), add 4M HCl in dioxane (3 mL), stir at room temperature for 3 hours, neutralize with saturated sodium bicarbonate aqueous solution after the reaction, extract with ethyl acetate, dry the organic phase over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain 6-fluoro-N-(methyl-d3)-5-(piperazin-1-yl)pyridineamide (Intermediate 29) (0.2 g, 81%) as a light yellow solid. ESI-MS m / z: 242 [M+H] +

[0119] N-Methyl-5-(piperazin-1-yl)picolinamide (Intermediate 32)

[0120]

[0121] The synthesis method refers to the preparation of 6-fluoro-N-methyl-5-(piperazine-1-yl)picolinamide (intermediate 26).

[0122] Pale yellow solid. ESI-MS m / z: 221[M+H] +

[0123] N-(Methyl-d3)-5-(piperazin-1-yl)picolinamide (Intermediate 33)

[0124]

[0125] The synthesis method refers to the preparation of 6-fluoro-N-(methyl-d3)-5-(piperazine-1-yl)pyridineamide (Intermediate 29), light yellow solid. ESI-MS m / z: 224 [M+H] +

[0126] N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 36)

[0127]

[0128] Preparation of 1'-(tert-butyl)6-methyl 3',6'-dihydro-[3,4'-bipyridine]-1',6(2'H)-dicarboxylate (Intermediate 34) Methyl 5-bromopicolinate (5.0 g, 23.15 mmol) and N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (10.7 g, 34.72 mmol) were dissolved in 1,4-dioxane (100 mL), and a solution of PdCl2(dppf) (168 mg, 0.23 mmol) and sodium carbonate (4.9 g, 46.3 mmol) in water (20 mL) were added. The mixture was heated to 80 °C and stirred for 16 hours under a nitrogen atmosphere. After the reaction was completed, water was added and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column. 1'-(tert-butyl)6-methyl 3',6'-dihydro-[3,4'-bipyridyl]-1',6(2'H)-dicarboxylate (Intermediate 34) (4.2 g, 57%) was obtained as a pale yellow solid. ESI-MS m / z: 319 [M+H] +

[0129] Preparation of tert-butyl 6-(methylcarbamoyl)-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (Intermediate 35)

[0130] The synthesis method refers to the preparation of tert-butyl 4-(2-fluoro-6-(methylcarbamoyl)pyridin-3-yl)piperazine-1-carboxylate (Intermediate 25), light yellow solid. ESI-MS m / z: 318 [M+H] +

[0131] Preparation of N-methyl-1', 2', 3', 6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 36) The synthesis method refers to the preparation of 6-fluoro-N-methyl-5-(piperazine-1-yl) pyridineamide (Intermediate 26), light yellow solid. ESI-MS m / z: 218 [M+H] +

[0132] N-(Methyl-d3)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 37)

[0133]

[0134] The synthesis method refers to the preparation of N-(methyl-d3)-5-(piperazine-1-yl)picolinamide (intermediate 33) and N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (intermediate 36). Pale yellow solid. ESI-MS m / z: 221 [M+H] +N-Methyl-5-(piperidin-4-yl)picolinamide (Intermediate 38)

[0135]

[0136] N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 36) (300 mg, 1.38 mmol) was dissolved in methanol (5 mL), 10% Pd-C (30 mg) was added, and the mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. After the reaction was completed, the mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain N-methyl-5-(piperidin-4-yl)pyridineamide (Intermediate 38) (280 mg, 93%) as an off-white solid. ESI-MS m / z: 220 [M+H] +

[0137] N-(Methyl-d3)-5-(piperidin-4-yl)picolinamide (Intermediate 39)

[0138]

[0139] The synthesis method refers to the preparation of N-methyl-5-(piperidin-4-yl) pyridine amide (Intermediate 38) and N-(methyl-d3)-5-(piperazine-1-yl) pyridine amide (Intermediate 33), light yellow solid. ESI-MS m / z: 223 [M+H] +

[0140] 2-Fluoro-N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 40)

[0141]

[0142] The synthesis method refers to the preparation of 5-bromo-6-fluoropicolinic acid methyl ester (intermediate 23) and N-methyl-1', 2', 3', 6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (intermediate 36), light yellow solid. ESI-MS m / z: 236 [M+H] +

[0143] 2-Fluoro-N-(methyl-d3)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 41)

[0144]

[0145] The synthesis method refers to 2-fluoro-N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 40)

[0146] Preparation of N-methyl-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxamide (Intermediate 36), pale yellow solid. ESI-MS m / z: 239 [M+H] +

[0147] Preparation of 6-fluoro-N-methyl-5-(piperidin-4-yl)picolinamide (Intermediate 42)

[0148]

[0149] The synthesis method refers to the preparation of 5-bromo-6-fluoropicolinic acid methyl ester (Intermediate 23) and N-methyl-5-(piperidin-4-yl)picolinamide (Intermediate 38), light yellow solid. ESI-MS m / z: 238 [M+H] +

[0150] 6-Fluoro-N-(methyl-d3)-5-(piperidin-4-yl)picolinamide (Intermediate 43)

[0151]

[0152] The synthesis method refers to the preparation of 5-bromo-6-fluoropicolinic acid methyl ester (Intermediate 23) and N-(methyl-d3)-5-(piperidin-4-yl)picolinamide (Intermediate 39), light yellow solid. ESI-MS m / z: 241 [M+H] +

[0153] Example 1: 5-(4-(7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide

[0154]

[0155] 7-(Bromomethyl)-3-cyclopropyl-1,5-naphthyridin-2(1H)-one (Intermediate 7) (100 mg, 0.36 mmol) and N-methyl-5-(piperazin-1-yl)pyridineamide (Intermediate 32) (95 mg, 0.43 mmol) were dissolved in NMP (2 mL), and DIPEA (0.12 mL, 0.72 mmol) was added. The mixture was heated to 80°C and stirred for 16 hours. After the reaction was completed, water was added and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting mixture was purified by preparative HPLC (column: Sunfire prep C18 column, 30x150mm, 5um; mobile phase A: water (0.1% HCO2H), mobile phase B: ACN; flow rate: 60mL / min; gradient: 10B to 35B in 8min; 254 / 220nm; RT: 7.37) was used for purification to obtain 5-(4-(7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide, (20mg, 13%) as a white solid. ESI-MS m / z: 419[M+H] +

[0156] 1 H NMR(400MHz, DMSO-d6)δ:11.85(s,1H),8.41(d,J=6.8Hz,1H),8.40-8.36(m,1H),8.27(d,J=8.8Hz,1H),7.83(d,J=6.8Hz,1H),7.76(s,1H),7.64(s ,1H),7.39(dd,J=4.4,12.6Hz,1H),3.66(s,2H),3.39-3.33(m,4H),2.79( d,J=6.4Hz,3H),2.59-2.53(m,4H),1.42-1.30(m,1H),0.43-0.21(m,4H).

[0157] Using the corresponding intermediates or starting materials, Examples 2-16 (see Table 2) were synthesized according to the basic operation similar to that of Example 1 to obtain the desired products.

[0158]

[0159]

[0160] Embodiment 17

[0161] Biological assay analysis

[0162] Evaluation of the inhibitory effect of the compounds of the present invention on PARP1 enzyme

[0163] Preparation of working stock solution:

[0164] All test compounds were serially diluted 3-fold with DMSO from 10 mM to 10 concentration levels. AZD9574 and AZD5305 were serially diluted 3-fold with DMSO from 0.05 mM to 10 concentration levels. All compounds were diluted 10-fold with 1X PARP buffer. Prepare 10X positive control (5 μM, AZD 9574 and AZD5305) and 10X negative control (100% DMSO), prepare 10X negative control (100% DMSO), shake the plate on a shaker for 5 minutes. Prepare PARP buffer: dilute 1 volume of 10X PARP buffer with 9 volumes of distilled water;

[0165] Compound Screening:

[0166] Prepare 1X histone mix in PBS, add 25 μM diluted histone solution to each well and incubate overnight at 4°C. Wash each well three times with 100 μM PBST buffer (1X PBS with 0.05% Tween 20). Tap the plate onto a clean paper towel to remove liquid. Block each well by adding 100 μM blocking buffer to each well and incubate at room temperature for 90 minutes. Wash each well 3 times with 100 μM PBST buffer and tap the plate onto a clean paper towel to remove liquid. Prepare 1X PARP assay mix and 1X activated DNA prepared with 1X PARP buffer. Add 12.5 μL of solution to each well of the assay plate, transfer 2.5 μL of compound dilution to each well of the assay plate; prepare PARP1 enzyme (lng / μl) with 1X PARP buffer. Start the reaction by adding 10 μL of PARP1 enzyme to each well of the assay plate. Shake for 30 seconds, 60 minutes at room temperature. After 1 hour, discard the reaction mixture and wash the plate three times with 100 μL PBST buffer and tap the plate onto a clean paper towel as before. Dilute Streptavidin-HRP 1:50 with blocking buffer. Add 25 μL of diluted Streptavidin-HRP to each well. Incubate at room temperature for 30 minutes. Wash each well three times with 100 μL PBST buffer. Tap the plate onto a clean paper towel to remove liquid. Before use, mix 25 μL HRP chemiluminescent substrate A and 25 μL HRP chemiluminescent substrate B on ice and add 50 μL to each well. Read the plate immediately using a microplate reader that can read the photometric intensity of luminescence.

[0167] Data analysis

[0168] The inhibition rate % was calculated as follows:

[0169]

[0170] Lum: Luminous intensity

[0171] Average luminescence of the positive control group (1um AZD9574 and AZD5305);

[0172] Mean luminescence of the negative control group (1% methyl sulfoxide);

[0173] Average luminescence of negative control group (1% methyl sulfoxide).

[0174] Calculation IC 50 And draw the effect dose curve of the compound

[0175] The percentage inhibition value and the logarithm of the compound concentration were subjected to nonlinear regression fitting (dose response-variable slope) using GRAPHPAD 5.0 ​​software to calculate the IC 50 value.

[0176] Y=Bottom + (Top-Bottom) / (1+10 - CT((LogIC 50 -X)*Hill Slope))

[0177] X:log of inhibitor concentration

[0178] Y:%Inhibition

[0179] result

[0180] Table 2. Inhibitory effect of the compounds of the present invention on PARP1 enzyme

[0181]

[0182]

[0183] The results showed that compared with AZD9574 and AZD5305, all the compounds of the present invention are highly effective PARP 1 inhibitors, indicating that structural optimization and modification can reflect better drug potential.

[0184] Example 18: Blood-brain barrier permeation assay

[0185] According to the literature (Journal of Medicinal Chemistry, 2013, 56(1):2-12) K p,uu脑 and K p,uu CSF Both are major parameters measured and optimized during CNS drug discovery. The relationship between the concentration of unbound drug in the brain and in the blood is p,uuBrain predictive drugs are used to target metastatic tumors in leptomeningeal metastases (LM), which are caused by metastatic spread of cancer to the leptomeninges, leading to central nervous system dysfunction. p,uu CSF Represents the distribution of a drug in the CSF compared to that in the blood, which drives drug response during treatment of leptomeningeal metastases.

[0186] In vitro blood and brain binding assays were carried out on HT dialysis plates with semipermeable membranes. Diluted blood (using DPBS1:1, pH is 7.4) and brain homogenate (with DPBS1:3, pH is 7.4) were spiked with 5 μM test compounds (triplicate) and at 37 ° C, dialyzed for 4 hours in a slowly rotating flat plate in an isovlasmic 100mM PBS buffer (pH7.4) of 150 μL. At the end of incubation, 50 μL of aliquots from the receiving side and 5 μL of aliquots from the donor chamber were taken. 5 μL samples were further diluted with 45 μL of blank blood or brain homogenate. Paired samples were matrix matched with buffer or blank blood / brain homogenate and mixed for 2 min, and then precipitated with 150 μL of cold acetonitrile with 100 ng / mL tolbutamide as internal standard. After centrifugation at 4000 rpm for 20 min, the supernatant was diluted with 0.1% formic acid in water and analyzed for LC / MS / MS. The unbound fraction (fu) of the test compound in brain homogenate and diluted blood was calculated by the ratio of the buffer side reaction to the brain homogenate / blood side reaction and was expressed using the following equation f u,bl (f u,br )=(1 / D) / [(1 / fu-1)+1 / D)] The unbound fraction (f) of the test compound in undiluted blood and tissue was calculated based on the measured fu in homogenate and diluted blood. u,bl and f u,br ). D is the dilution factor.

[0187] Short-term oral absorption (SOA) model is an in vivo screening model for identifying the brain penetration of a compound. The compound of 2mg / kg in 1% methylcellulose was orally administered to six male wistar rats. After administration 0.25 hour, 0.5 hour, 1 hour, 2 hours, 4 hours and 7 hours, cerebrospinal fluid (CSF) was collected from the cisterna magna, and blood samples (>60 μL / time point / each position) were collected in a separate EDTA coagulation test tube via cardiac puncture, and then diluted immediately with 3 times of volume of water. Harvest brain tissue and homogenize in 3 times of volume of phosphate buffered saline (pH is 7.4). Before LC / MS / MS analysis, all samples were stored at approximately -70 ℃.

[0188] Standards were prepared by spiking blank blood, brain homogenate and 0.2ng / mL to 500ng / mL artificial CSF. Homogenized brain tissue was precipitated together with blood samples by adding 3 volumes of cold acetonitrile containing internal standards (40ng / mL dexamethasone and 40ng / mL diclofenac), and 10 μL of CSF samples were precipitated with 100 μL of cold acetonitrile containing internal standards. After vortexing for 2min and centrifuging for 5min at 14,000rpm, the supernatant was analyzed by LC / MS / MS. Two groups of standard curves were run at the beginning and end of each batch of blood sample analysis. For brain samples and CSF samples, standard curves were made together with test samples.

[0189] After oral administration, the ratio of brain to blood (K) was expressed as AUC brain / AUC blood in rodents. p The free fraction of the test compound in the biological matrix was determined by in vitro blood and brain binding assays. K was calculated by the following equation p,uu脑 and K p,uu CSF :K p,uu脑 =AUC 脑 / AUC 血液 ×(f u,脑 / f u.血液 ) and K p,uu CSF =AUC CSF / (AUC 血液 ×f u.血液 ).

[0190] In the table below are shown the data determined for the examples of the present invention and the data obtained for AZD5305 and AZD9574:

[0191] Table 3. Experimental data on brain barrier permeability of the embodiments of the present invention, AZD5305 and AZD9574

[0192]

[0193]

[0194] When compared with AZD5305, the compound of the present invention has superior brain barrier permeability, and when compared with AZD9574, the compound of the present invention has unexpectedly better brain barrier permeability. Drugs for treating brain tumors need to enter the brain to exert their effects. Conventional drugs are not exposed to sufficient amounts in the brain due to the obstruction of the blood-brain barrier, thus limiting their efficacy. The improvement of the blood-brain barrier permeability effectively increases the drug concentration in the brain, which plays a vital role in controlling tumors and improving drug efficacy.

[0195] For compounds of the general formula (I), the linking groups and substituent groups have an important influence on the pharmacodynamic properties and brain barrier permeability of the compounds. Although the present invention is illustrated by the specific examples above, it should not be construed as being limited thereto; rather, the present invention encompasses the general aspects previously disclosed. Various modifications and embodiments may be made without departing from the spirit and scope of the present invention.

[0196] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A compound represented by the following formula (I) and a pharmaceutically acceptable salt thereof: in, R1 is selected from hydrogen, C1-C6 alkyl or C3-C8 cycloalkyl; R2 and R3 are each independently selected from H, halo, C1-C3 alkyl, deuterated C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy; R4 is selected from C1-C3 alkyl, deuterated C1-C3 alkyl, halogenated C1-C3 alkyl, C1-C3 alkoxy; A and B are each independently selected from N and C(H), provided that A and B are not N or C(H) at the same time; X is selected from N and C(H); It can be single key or double key.

2. The compound represented by formula (I) and a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R1 is selected from C1-C4 alkyl or C3-C6 cycloalkyl, preferably methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl; more preferably hydrogen, methyl, ethyl, cyclopropyl; R2 and R3 are each independently selected from H and halo, the halo is preferably selected from fluorine, chlorine, bromine; more preferably fluorine; R4 is selected from methyl or methyl substituted with 1 to 3 deuterium atoms; more preferably methyl or deuterated methyl; Preferably, A and B are each independently selected from N and C(H); Preferably, X is selected from N and C(H); It can be single key or double key.

3. The compound represented by formula (I) and a pharmaceutically acceptable salt thereof according to claim 2, characterized in that: The compound of general formula (I) or a pharmaceutically acceptable salt thereof is one of the following compounds:

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt is an inorganic salt or an organic salt; wherein the inorganic salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; and the organic salt is selected from format, acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, succinate, glutarate, fumarate, maleate, lactate, malate, citrate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, salicylate, p-toluenesulfonate, and ascorbate.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (I) according to any one of claims 1 to 3 and a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier, excipient or diluent.

6. Use of the compound represented by formula (I) according to any one of claims 1 to 4 and a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 5 in the preparation of a medicament for use as a PARP1 inhibitor.

7. Use of the compound represented by formula (I) according to any one of claims 1 to 4 and its pharmaceutically acceptable salt or the pharmaceutical composition according to claim 5 in the preparation of a therapeutic drug for PARP1-related diseases; The PARP1-related disease is cancer, including breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, blood cancer, gastric cancer, intestinal cancer, or lung cancer.

Citation Information

Patent Citations

  • Pyridine derivative and application thereof in medicine

    CN115232121A

  • PARP1 inhibitor and application thereof

    CN117177972A

  • Compounds as PARP inhibitors

    CN117321051A

  • Quinoxaline compound and medical application thereof

    CN118496203A

  • PARP1 inhibitors and uses thereof

    WO2023146960A1

Cited By

  • Pyridine derivative and application thereof in medicine

    CN116867784A

  • Pyridine derivatives and their use in medicine

    CN116867784B

  • Salt form of PARP inhibitor-fused heterocyclic deuterated compound, and preparation method therefor and use thereof

    WO2025218777A1